US Patent

US10562934 — Modulation of complement activity

Composition of Matter · Assigned to Ra Pharmaceuticals Inc · Expires 2035-06-12 · 9y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects modulators of complement activity and methods of using them as therapeutics.

USPTO Abstract

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Drugs covered by this patent

Patent Metadata

Patent number
US10562934
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-06-12
Drug substance claim
Yes
Drug product claim
No
Assignee
Ra Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.